Clinical trials: Corticobasal Degeneration (CBD)
Progressive Supranuclear Palsy, Corticobasal Degeneration
Wellness in PSP and CBD
The goal of this interventional study is to evaluate the feasiblity and effectiveness of a multimodal lifestyle program for individuals living with Progressive Supranuclear Palsy or Corticobasal Deneration.
- Trial name
- NCT07844655
- Testing
- Exercise and Peer Support
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Silke Cresswell
Progressive Supranuclear Palsy, Corticobasal Degeneration
Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration
Drug therapy of atypical parkinsonism is generally considered either ineffective or minimal 1. Therefore, there is an urgent need to find alternative therapies to treat atypical parkinsonian disorders.
- Conditions
- Progressive Supranuclear Palsy, Corticobasal Degeneration, Parkinsonism
- Trial name
- NCT01174771
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
PSP, PSP - Progressive Supranuclear Palsy
The CurePSP Genetics Program
This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurological conditions and their families.
- Conditions
- PSP, PSP - Progressive Supranuclear Palsy, Corticobasal Syndrome, Corticobasal Syndrome(CBS)
- Trial name
- NCT06647641
- Testing
- Whole genome sequencing will be performed at the NIH
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Cortico Basal Degeneration, Corticobasal Syndrome
Imaging Studies in Corticobasal Syndrome
The primary goal of this study is to investigate inflammation and white matter damage in corticobasal syndrome and determine whether these processes are related to each other.
- Conditions
- Cortico Basal Degeneration, Corticobasal Syndrome, Corticobasal Syndrome(CBS), Corticobasal Degeneration
- Trial name
- I-CAN (NCT07000851)
- Testing
- C-11 ER176 Radiotracer, C-11 PiB, AV1451 Tau
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Jennifer Whitwell
Vascular Parkinsonism, Drug-induced Parkinsonism
AI-Enhanced Optimization of Acute Levodopa Challenge Test
A quantitative evaluation method was developed for Parkinson's disease and other atypical parkinonism by integrating an innovative motor paradigm with perception technologies and artificial intelligence.
- Conditions
- Vascular Parkinsonism, Drug-induced Parkinsonism, Corticobasal Degeneration (CBD), Parkinson Disease (PD)
- Trial name
- NCT06949865
- Testing
- video recording
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Beijing Tiantan Hospital
Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS)
Safety Study of TPI-287 to Treat CBS and PSP
The purpose of this study is to determine the safety and tolerability [maximum tolerated dose (MTD) within planned dosing range] of intravenous (IV) infusions of TPI 287 administered once every 3 weeks for 9 weeks (for a total of…
- Conditions
- Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
- Trial name
- TPI-287-4RT (NCT02133846)
- Testing
- TPI 287 2 mg/m2, TPI-287 20 mg/m2, TPI-287 6.3 mg/m2
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- University of California, San Francisco
Progressive Supranuclear Palsy, Corticobasal Degeneration
Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers
This study will evaluate flortaucipir for brain imaging of tau in subjects with progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and healthy volunteers.
- Trial name
- NCT02167594
- Testing
- Flortaucipir F18, Brain PET scan
- Where
- 5 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Multiple System Atrophy, Dementia With Lewy Bodies (DLB)
Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH)
This goal of this observational study is to clarify the variations in the natural course of atypical parkinsonian syndromes (APS, including MSA, DLB, PSP, and CBD), such as the progression rate of motor and non-motor symptoms and…
- Conditions
- Multiple System Atrophy, Dementia With Lewy Bodies (DLB), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
- Trial name
- NCT07805967
- Testing
- We did not apply any interventions; only observational research was conducted.
- Where
- 20 sites in China
- Volunteers
- 500 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Primary Tauopathies, Corticobasal Degeneration Syndrome
BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel Cohort Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Intravenously Infused BIIB092 in Patients with Four Different…
- Conditions
- Primary Tauopathies, Corticobasal Degeneration Syndrome, Frontotemporal Lobar Degeneration With Tau Inclusions, MAPT Mutation Carriers, Symptomatic
- Trial name
- TauBasket (NCT03658135)
- Testing
- BIIB092
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of California, San Francisco
Essential Tremor, Multiple System Atrophy
Defining Phenotypes of Movement Disorders :Parkinson's Plus Disorders (PD), Essential Tremor (ET), Cortical Basal Degeneration (CBD), Multiple Systems Atrophy (MSA), Magnetoencephalography.
Investigators hypothesize that there are specific characteristic of each cognitive and motor condition that can be defined using brains scans.
- Conditions
- Essential Tremor, Multiple System Atrophy, Corticobasal Degeneration, Supranuclear Palsy, Progressive
- Trial name
- PHENO (NCT02132052)
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of Colorado, Denver
Primary Tauopathy Corticobasal Degeneration Syndrome (CBD)
Expanded Access to ABBV-8E12
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABBV-8E12 prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Trial name
- NCT03744546
- Testing
- ABBV-8E12
- Sponsor
- AbbVie
Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS)
4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2
The goal of this study is to identify the most reliable methods of analysis for tracking CBD, PSP, and o/vPSP over time. The results from this study may be used in the future to calculate statistical power for clinical drug…
- Conditions
- Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS), Cortical-basal Ganglionic Degeneration (CBGD), Progressive Supranuclear Palsy (PSP)
- Trial name
- 4RTNI-2 (NCT02966145)
- Testing
- Observational Study
- Where
- 8 sites in United States, Canada
- Volunteers
- 293 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
FTLD, Progressive Supranuclear Palsy (PSP)
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)
Frontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes: frontotemporal dementia (FTD), primary…
- Conditions
- FTLD, Progressive Supranuclear Palsy (PSP), Frontotemporal Dementia (FTD), Corticobasal Degeneration (CBD)
- Trial name
- ARTFL (NCT02365922)
- Where
- 17 sites in United States, Canada
- Volunteers
- 1,489 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Alzheimer Disease (AD), Frontotemporal Lobar Degeneration
ADDIA Proof-of-Performance Clinical Study
The objective of the ADDIA clinical Proof-of-Performance study is to validate the performance of ADDIA' blood biomarkers for diagnosis of Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease (AD), Frontotemporal Lobar Degeneration, Dementia with Lewy Bodies (DLB), Parkinson Disease Dementia (PDD)
- Trial name
- ADDIA (NCT03030586)
- Testing
- volumetric MRI
- Where
- 13 sites in Belgium, France and 3 more
- Volunteers
- 821 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Predicted Tauopathies, Including, Progressive Supranuclear Palsy
Davunetide (AL-108) in Predicted Tauopathies - Pilot Study
The primary objective of the study is to obtain preliminary safety and tolerability data with davunetide (NAP, AL-108) in patients with a tauopathy (frontotemporal lobar degeneration [FTLD] with predicted tau pathology…
- Conditions
- Predicted Tauopathies, Including, Progressive Supranuclear Palsy, Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17, Corticobasal Degeneration Syndrome
- Trial name
- NCT01056965
- Testing
- davunetide (AL-108, NAP)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, San Francisco
Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP)
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American…
- Conditions
- Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD)
- Trial name
- NCT04363684
- Where
- 26 sites in United States, Canada
- Volunteers
- 2,100 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Progressive Supranuclear Palsy, Corticobasal Degeneration
A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration
The goal of this trial is to evaluate the safety and tolerability of lithium in people with progressive supranuclear palsy or corticobasal degeneration.
- Trial name
- NCT00703677
- Testing
- Lithium
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 17 people
- Sponsor
- Westat
Progressive Supranuclear Palsy, Cortical Basal Ganglionic Degeneration
tDCS as Treatment for Motor Function
Previous preliminary results are sufficiently impressive to suggest that tDCS stimulation does have the potential to improve motor function when that ability is trained during stimulation.
- Conditions
- Progressive Supranuclear Palsy, Cortical Basal Ganglionic Degeneration, Parkinson Disease
- Trial name
- PSP (NCT07291687)
- Testing
- Transcranial direct current stimulation (TDCS), Stimulation Arm
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Baycrest
PSP, CBD
A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes
The primary objective of this study is to enroll an observational cohort of approximately 60 patients with PSP over the course of 24 months using a multicenter study design and to follow each of them for 12 months.
- Conditions
- PSP, CBD, Progressive Supranuclear Palsy, FTD
- Trial name
- NCT05956834
- Testing
- PAMSys, LEGSys
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
Human CNS Tau Kinetics in Tauopathies
The goal of this study is to characterize tau kinetics and tau aggregation in the human CNS and to test the hypothesis that tau kinetics are altered (i.e.
- Conditions
- Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Frontotemporal Dementia (FTD MAPT Mutation)
- Trial name
- TANGLES (NCT03545126)
- Testing
- 13C6 Leucine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Washington University School of Medicine